Leerink: Translate Bio's Cystic Fibrosis Candidate Could Generate $1.8B

Leerink sees potential in Translate Bio Inc TBIO mRNA-based candidate for cystic fibrosis patients with Class I mutations.

The Analyst

Leerink's Geoffrey Porges initiated coverage of Translate Bio with an Outperform rating and $24 price target. 

The Thesis

Around 12 percent of patients with cystic fibrosis have Class I mutations — the most severe form of cystic fibrosis and one with no therapeutic treatment, Porges said in the initiation note. (See the analyst's track record here.) 

Patients with the Class I mutation cannot produce the cystic fibrosis transmembrane conductance regulator protein and do not respond to CFTR correctors and potentiators, the analyst said. 

Translate Bio is developing MRT5005, which encodes for a functional CFTR protein when it is delivered by a nebulizer to the lung, Porges said. The drug recently entered a Phase I/II clinical trial in adults with Class I and II mutations in cystic fibrosis, and safety and early results are expected in the fourth quarter. 

Porges said he expects the product to reach $1.8 billion in revenue from Class I cystic fibrosis patients if approved. He forecast a 15-percent probability for successful development in Class I cystic fibrosis and a 10-percent probability for success in other mutations.

Leerink projects a drug launch in late 2022 and for Translate's break-even point to come in 2026. The biotech will need additional financing during its development phase, Porges said. 

The Price Action

Translate shares were down 0.25 percent at $15.90 at the close Monday. 

Related Links:

The Week Ahead: FANG Earnings Continue, Fox Vote On Disney Deal, More IPOs

Translate Bio's Novel mRNA Therapy Candidate Addresses A Key Investor Concern, Citi Says

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorBiotechPrice TargetInitiationAnalyst RatingsGeneralGeoffrey PorgesLeerink
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!